| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
QuidelOrtho Corporation$18
-0.25 (-1.37%)
Market Cap
808.75 M
EPS
-17.82
P/E Ratio
-
Value Trade
24.76 M
SEC Financials
Q1 2026Dilution Risk
50%Revenue
619.80 M
R&D Expenses
44.90 M
Operating CF
-33.00 M
Total Assets
5.63 B
Total Liabilities
3.78 B
Equity
1.85 B
D/E Ratio
12,345
4.13 %
Week
-2.47 %
1 Month
-49.32 %
3 Month
-47.12 %
6 Month
-90.2 %
5 Year
131.41 %
All Time
Cash Data
Cash Position
140.40 M
Monthly Burn
11.00 M
Runway
10.9 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
1.06 M
52 Week Range
9.92 - 35.58
% held by Insiders
1.18 %
% held by Institutions
124.55 %
Enterprise Value
3.54 B
Total Shares
68.06 M
Short %
18.33 %
Float Shares
67.45 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QDEL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QDEL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QDELQuidelOrtho Appoints Micah Young as Chief Financial Officer
QuidelOrtho Corporation has appointed Micah Young as Chief Financial Officer, effective July 6, 2026. Young succeeds Joseph M. Busky, who will assist in the transition. Young has extensive experience in medical technology finance and aims to enhance profitability and shareholder value at QuidelOrtho.
Read more →QDELWhen Blood Compatibility Becomes a Pregnancy Risk
QuidelOrtho Corporation has released a podcast episode discussing hemolytic disease of the fetus and newborn (HDFN), emphasizing the impact of maternal alloimmunization. The episode highlights the importance of awareness, timely diagnostics, and coordinated care to improve outcomes. Despite advancements, significant gaps in understanding and care persist, affecting patient management.
Read more →QDELQuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
QuidelOrtho Corporation announced its participation in two upcoming investor conferences in June 2026. The management team will present at the William Blair 46th Annual Growth Stock Conference and engage in a fireside chat at the Jefferies Global Healthcare Conference. Interested parties can access the events via the company's Investor Relations page.
Read more →QDELQuidelOrtho Reports First Quarter 2026 Financial Results
QuidelOrtho Corporation reported its first-quarter financial results for 2026, highlighting a weaker respiratory season and disruptions in key markets. Despite these challenges, the company remains optimistic about its growth prospects, particularly following its acquisition of LEX Diagnostics and the launch of new products. The company has updated its financial guidance for the year, factoring in current market dynamics.
Read more →QDELUnderstanding and Addressing Syphilis Trends - and What's Being Missed
QuidelOrtho Corporation's latest podcast episode discusses the concerning rise in congenital syphilis cases in the U.S., despite a decline in early-stage infections. Hosted by Josh Casey, the episode features insights from Andrea Ott-Vasconi on CDC data and emphasizes the need for improved diagnostic strategies and healthcare workflows. The discussion highlights missed screening opportunities and actionable steps to enhance prenatal care.
Read more →QDELQuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
QuidelOrtho Corporation has successfully acquired LEX Diagnostics for approximately $100 million, enhancing its molecular diagnostics capabilities. The LEX VELO System, which has received FDA clearance, offers rapid RT-PCR testing for Influenza A, Influenza B, and COVID-19. The company plans to launch this system commercially in the U.S. later this year, aiming to improve patient outcomes through faster diagnostics.
Read more →QDELTTP Group Announces the Sale of LEX Diagnostics
TTP Group has announced the sale of LEX Diagnostics. Details regarding the transaction and its implications for TTP Group and LEX Diagnostics are not provided in the article. The announcement suggests a strategic move by TTP Group, although specifics are lacking.
Read more →QDELQuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
QuidelOrtho Corporation announced preliminary unaudited revenue of $615-$620 million for Q1 2026, driven by a weaker respiratory season and slower sales in China. The company remains optimistic about its core business, which constitutes over 70% of total revenue. However, it faces challenges from external factors, including geopolitical issues and reimbursement rate changes. A detailed financial report is expected on May 5, 2026.
Read more →QDELNathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
QuidelOrtho Corporation has appointed Nathaniel Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky, who has over 25 years of experience in legal and governance roles, succeeds Michelle Hodges, who is retiring. He aims to support the company's mission of advancing diagnostics and improving patient care.
Read more →QDELQuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results
QuidelOrtho Corporation reported strong financial results for Q4 and FY25, highlighting a transition to a more stable diagnostics business. The company achieved notable growth in Labs and TRIAGE™ segments, along with significant margin expansion. Looking ahead, QuidelOrtho anticipates improved free cash flow in FY26, although the retirement of CFO Joseph M. Busky raises some concerns about future financial management.
Read more →QDELQuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results
QuidelOrtho Corporation will announce its financial results for Q4 and the full year 2025 on February 11, 2026. Following this release, a conference call will be held to discuss the results. Interested parties can access the call via the company's website or by phone. A replay will be available afterward.
Read more →QDELQuidelOrtho Reports Third Quarter 2025 Financial Results Total revenue of $700 million excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum Successful
QuidelOrtho Corporation reported its third quarter 2025 financial results, with total revenues of $700 million, representing a 4% decrease from the previous year. The decline was primarily attributed to lower COVID-19 and Donor Screening revenues. Despite this, the company announced a successful debt refinancing which enhances financial flexibility and reported a rise in adjusted EBITDA margin to 25%. Adjusted diluted earnings per share were $0.80 for this quarter, slightly down from $0.85 in the prior year.
Read more →QDELQuidelOrtho Announces Appointment of Two Independent Directors to its Board Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to
QuidelOrtho Corporation announced the appointment of John R. Chiminski and R. Scott Huennekens as independent directors to its board, effective December 6, 2024. This decision is aimed at strengthening the board's leadership and operational expertise, with both appointees bringing extensive experience in the healthcare sector. CEO Brian J. Blaser expressed optimism that their involvement will help execute the company's transformational strategy and improve financial results. The appointments stem from a thorough search process conducted by the Nominating and Corporate Governance Committee.
Read more →QDELQuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group
QuidelOrtho Corporation has announced the pricing of a secondary offering of 8,260,183 shares of its common stock by Carlyle Partners VI Cayman Holdings, L.P. The offering is being underwritten solely by Goldman Sachs & Co. LLC and is expected to close on November 21, 2024, pending customary conditions. QuidelOrtho will not receive any proceeds from this offering, as all funds will go to the selling stockholder. The offering is made under an effective shelf registration statement filed with the SEC.
Read more →QDELAbout QuidelOrtho Corporation QuidelOrtho Corporation (Nasdaq QDEL) is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more
QuidelOrtho Corporation has announced the appointment of Brian J. Blaser as its new President and Chief Executive Officer, effective May 6, 2024. Blaser brings over 25 years of leadership experience in the in-vitro diagnostics sector, previously serving as Executive Vice President at Abbott Laboratories. He expressed eagerness to lead the company through its next growth phase, emphasizing a commitment to customer service and improving healthcare outcomes. The Board of Directors also acknowledged the prior leadership during this transition period and is set to expand with Blaser's joining.
Read more →QDELQuidelOrtho Reports Second Quarter 2023 Financial Results Highligh ts Second quarter revenue of $665.1 million increased by 8% as reported with non-respiratory revenue up 3% on a supplemental combined basis (up 4% in con
QuidelOrtho Corporation reported its second quarter 2023 financial results, with total revenue of $665.1 million, reflecting an 8% increase compared to the previous year. However, while non-respiratory revenue grew by 9%, respiratory revenue saw a significant decline of 74%, leading to an adjusted EPS decrease of 88%. The company has completed important regulatory submissions and is focusing on further synergies from operational integration. Overall, the results indicate both a strong performance in certain areas and significant challenges in respiratory segments.
Read more →QDELQuidelOrtho Reports First Quarter 2023 Financial Results Highligh ts First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in cons
QuidelOrtho Corporation reported its financial results for Q1 2023, revealing a total revenue of $846.1 million, a significant decrease of 16% from the prior year. While non-respiratory revenue increased by 5%, respiratory sales plummeted by 72%. The company also reported a GAAP diluted EPS of $0.73, down dramatically from $11.31 in Q1 2022. Despite these challenges, QuidelOrtho's management expresses confidence in future growth, citing solid demand in its Labs business and effective integration efforts.
Read more →QDELQuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results Highlights Fourth quarter revenue of $866.5 million increased by 36% as reported and 19% on a supplemental combined basis, excluding COVID-19 revenu
QuidelOrtho Corporation reported its financial results for the fourth quarter and full year of 2022, highlighting substantial revenue growth. For Q4, revenue was $866.5 million, reflecting a 36% year-over-year increase, driven largely by performance in Point of Care and Molecular Diagnostics businesses. However, the company faced challenges, including a significant decrease in GAAP EPS compared to the previous year and adverse impacts from supply chain issues and COVID-19 related factors in the Labs segment. Overall, while the company reported robust revenue figures, profitability metrics showed concerning declines.
Read more →QDELQUIDELORTHO ANNOUNCES SEPARATION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER ROLES Lead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman Douglas Bryant to continue as Chief Executive Officer an
QUIDELORTHO ANNOUNCES SEPARATION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER ROLES Lead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman Douglas Bryant to continue as Chief Executive Officer and Director Assumes role as President SAN DIEGO, CA - Quid
Read more →QDELQuidelOrtho Reports Third Quarter 2022 Financial Results Highlights Revenue of $783.8 million increased by 54% as reported Supplement al combined revenue of $783.8 million decreased by 21.8% in constant currency and incr
QuidelOrtho Reports Third Quarter 2022 Financial Results Revenue of $783.8 million increased by 54% as reported Supplemental combined revenue of $783.8 million decreased by 21.8% in constant currency and increased 3.0%, excluding COVID-19 revenue the transition of Beckman BNP a
Read more →QDELRanked among the world's largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint
QUIDELORTHO REPORTS PRELIMINARY REVENUE RESULTS FOR THIRD QUARTER 2022 QuidelOrtho to Report Third Quarter 2022 Financial Results on November 2, 2022 SAN DIEGO, CA - October 12, 2022 - QuidelOrtho Corporation (NASDAQ QDEL) (the "Company" or "QuidelOrtho"), a global provider of
Read more →QDELamong others, could cause actual results to differ from those set forth in the forward-looking statements the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the busi
QUIDELORTHO ANNOUNCES $300 MILLION SHARE REPURCHASE AUTHORIZATION Reflects QuidelOrtho's confidence in its strong balance sheet and cash generation QuidelOrtho continues to prioritize investments in R D, manufacturing capacity, and debt paydown SAN DIEGO, CA - August 17, 2022
Read more →QDELQuidelOrtho Reports Second Quarter 2022 Financial Results Highlights Revenue of $613.4 million increased by 247% as reported Supplement al combined revenue of $898.5 million increased by 37.5% in constant currency and 9.
QuidelOrtho Reports Second Quarter 2022 Financial Results Revenue of $613.4 million increased by 247% as reported Supplemental combined revenue of $898.5 million increased by 37.5% in constant currency and 9.0%, excluding COVID-19 revenue Strong growth in all business units, ex
Read more →Competitive Position
How QDEL ranks across every disease it competes inCompetitive Position is a premium feature
See how QDEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial